ANDA 204860, held by Nexus Pharmaceuticals. Prochlorperazine Edisylate.
As of Nov 21, 2026, ANDA 204860 (Prochlorperazine Edisylate), held by Nexus Pharmaceuticals, was first approved by FDA on Feb 15, 2019, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 15, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prochlorperazine EdisylateEQ 5MG BASE/ML · injectable;injection | Prochlorperazine Edisylate | Discontinued |
| Feb 19, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 15, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters